Person:
ÖZTEN KANDAŞ, NUR

Loading...
Profile Picture
Status
Kurumdan Ayrılmıştır
Organizational Units
Job Title
First Name
NUR
Last Name
ÖZTEN KANDAŞ
Name
Email Address
Birth Date

Search Results

Now showing 1 - 10 of 17
  • PublicationMetadata only
    Comparison of laser and ozone treatments on oral mucositis in an experimental model
    (2017-04-01T00:00:00Z) BAYER, SUZAN; Kazancioglu, Hakki Oguz; Acar, Ahmet Huseyin; Demirtas, Nihat; ÖZTEN KANDAŞ, NUR; BAYER, SUZAN; ÖZTEN KANDAŞ, NUR
    Oral mucositis (OM) induces severe pain and limits fundamental life behaviors such as eating, drinking, and talking for patients receiving chemotherapy or radiotherapy. In addition, through opportunistic microorganisms, OM frequently leads to systemic infection which then leads to prolonged hospitalization. Severe lesions often adversely affect curative effects in cancer cases. Therefore, the control of OM is important for oral health quality of life and prognosis. Low-level laser therapy (LLLT) and ozone may be useful to accelerate wound healing. In this study, 24 Sprague-Dawley rats were divided into three groups as control, ozone, and laser groups. All groups received 5-fluorouracil intraperitoneally and trauma to the mouth pouch with a needle. After the formation of OM in the mouth, the control group had no treatment; the ozone group was administered ozone, and the laser group, LLLT. Then, all groups were sacrificed and basic fibroblast growth factor (bFGF), transforming growth factor (TGF-beta), and platelet-derived growth factor (PDGF) were evaluated in all groups. LLLT was determined to be statistically significantly more effective than ozone on FGF and PDGF. However, in respect of TGF-beta, no statistically significant difference was observed between the groups. In conclusion, within the limitations of this study, LLLT is more effective than ozone. However, further studies on this subject are required.
  • PublicationMetadata only
    Mikroenkapsüle edilen paratiroid hücrelerinin in-vitro optimizasyonu
    (2017-12-01) YUCESAN, Emrah; GONCU, Beyza; BAŞOĞLU, HARUN; ÖZTEN KANDAŞ, NUR; ERSOY, YELİZ EMİNE; AKBAŞ, FAHRİ; AYŞAN, MUSTAFA ERHAN; BAŞOĞLU, HARUN; GÖNCÜ, BEYZA SERVET; ÖZTEN KANDAŞ, NUR; ERSOY, YELIZ EMINE; AKBAŞ, FAHRİ; AYŞAN, MUSTAFA ERHAN
  • PublicationMetadata only
    NEW TRANSPORT SOLUTION FOR PARATHYROIDALLOTRANSPLANTATION (FR) (NFR)
    (2017-09-27) GONCU, Beyza; OZDEMIR, Burcu; BAŞOĞLU, HARUN; ÖZTEN KANDAŞ, NUR; AKBAŞ, FAHRİ; KESKİN TOKA, Cemile; YUCESAN, Emrah; KAZANCIOĞLU, RÜMEYZA; AYŞAN, MUSTAFA ERHAN; GÖNCÜ, BEYZA SERVET; BAŞOĞLU, HARUN; ÖZTEN KANDAŞ, NUR; AKBAŞ, FAHRİ; KAZANCIOĞLU, RÜMEYZA; AYŞAN, MUSTAFA ERHAN
  • PublicationOpen Access
    Cancer chemoprevention research with selenium in the post-SELECT era: Promises and challenges.
    (2016-01-01) LÜ, J; ZHANG, J; JIANG, C; DENG, Y; Özten, NUR; BOSLAND, MC; ÖZTEN KANDAŞ, NUR
    The negative efficacy outcomes of double-blinded, randomized, placebo-controlled Phase III human clinical trials with selenomethionine (SeMet) and SeMet-rich selenized-yeast (Se-yeast) for prostate cancer prevention and Se-yeast for prevention of non-small cell lung cancer (NSCLC) in North America lead to rejection of SeMet/Se-yeast for cancer prevention in Se-adequate populations. We identify two major lessons from the outcomes of these trials: 1) The antioxidant hypothesis was tested in wrong subjects or patient populations. 2) The selection of Se agents was not supported by cell culture and preclinical animal efficacy data as is common in drug development. We propose that next-generation forms of Se (next-gen Se), such as methylselenol precursors, offer biologically appropriate approaches for cancer chemoprevention but these are faced with formidable challenges. Solid mechanism-based preclinical efficacy assessments and comprehensive safety studies with next-gen Se will be essential to re-vitalize the idea of cancer chemoprevention with Se in the post-SELECT era. We advocate smaller mechanism-driven Phase I/II trials with these next-gen Se to guide and justify future decisions for definitive Phase III chemoprevention efficacy trials.
  • PublicationOpen Access
    Synthesis and biological evaluation of novel coumarin-chalcone derivatives containing urea moiety as potential anticancer agents
    (2017-12-01) ZENGİN KURT, BELMA; ÖZTEN KANDAŞ, NUR; DAĞ, AYDAN; SÖNMEZ, FATİH; KÜÇÜKİSLAMOĞLU, MUSTAFA; ÖZTEN KANDAŞ, NUR
  • PublicationMetadata only
    Interactive effects of 9-cis-retinoic acid and androgen on proliferation, differentiation, and apoptosis of LNCaP prostate cancer cells.
    (2017-01-01) ESKRA, JN; KUIPER, JW; WALDEN, PD; BOSLAND, MC; Özten, NUR; ÖZTEN KANDAŞ, NUR
  • PublicationMetadata only
    Achieving the balance: Biphasic effects of genistein on PC-3 cells
    (2019-08-01T00:00:00Z) Goncu, BEYZA; Yildiz, Mehmet Taha; Ozten-Kandas, Nur; GÖNCÜ, BEYZA SERVET; ÖZTEN KANDAŞ, NUR
    This study examined the response of PC-3 cells to physiological (0.5, 2.5, 5, 10 mu M) and pharmacological (50 mu M) concentrations of genistein which is a main bioactive compound in soy. Following 48 hr genistein treatment, cell-based assays and genome-wide microarray were performed. It was evidenced that maximal physiologically achievable concentrations of genistein (0.5-10 mu M) lead to significant increase in cell viability (p 10 mu M) appeared to have a novel mechanism of action, specifically down-regulating TGF-beta by decreasing specifically SMAD 2/3,4 which are in the downstream TGF-beta signaling cascade. Practical applications This study highlights for the first time that maximal physiologically achievable concentrations of genistein (0.5-10 mu M) have proliferative effects evidenced by alterations in global gene expression patterns of PC-3 cells. Our results particularly represent a closer examination of dietary genistein consumption for the prevention and/or treatment of cancer that maximal physiologically achievable concentrations of genistein could have detrimental effects on individuals with prostate cancer. Further studies as in vivo would be necessary to remove shadows on the effect of genistein on prostate cancer progression.
  • PublicationMetadata only
    Pharmacogenetics: Role of Single Nucleotide Polymorphisms
    (2019-01-01T00:00:00Z) YÜCESAN, Emrah; ÖZTEN KANDAŞ, NUR; ÖZTEN KANDAŞ, NUR
    Genome sequencing methods have basically similar algorithms, although they show a few differences between the platforms. The human genome contains approximately three billion base pairs, and this amount is huge and therefore impossible to sequence at one step. However, this amount is not a problem for developed technology. Researchers break DNA into small random pieces and then sequence and reassemble. Library preparation, sequencing, bioinformatic approaches and reporting. High-quality library preparation is critical and the most important part of the next-generation sequencing workflow. Successful sequencing directly requires high-quality libraries. Sequencing is second step and all high-throughput sequencing approaches are generally based on conventional Sanger sequencing. After preparation of library and sequencing, later steps are completely computer-based (in silico) approaches called as bioinformatics.
  • PublicationMetadata only
    Low Dose Genistein Unlikely Induces Proliferation of PC3 Cells
    (2017-05-25) TERZİOĞLU UŞAK, ŞULE; ÖZTEN KANDAŞ, NUR; TERZİOĞLU, ŞULE; ÖZTEN KANDAŞ, NUR
  • PublicationMetadata only
    Bezmialem Taşıma Solüsyonu®’nun Soğuk İskemi Süresince Verimliliğinin Paratiroid Hücreleri İncelenerek Belirlenmesi
    (2017-12-03) GONCU, Beyza; YUCESAN, Emrah; OZDEMIR, Burcu; KESKİN TOKA, Cemile; BAŞOĞLU, HARUN; ÖZTEN KANDAŞ, NUR; AKBAŞ, FAHRİ; AYŞAN, MUSTAFA ERHAN; BAŞOĞLU, HARUN; ÖZTEN KANDAŞ, NUR; AKBAŞ, FAHRİ; AYŞAN, MUSTAFA ERHAN